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Objectives The goal of this study was to compare the rate of cerebral microembolization during carotid artery stenting
(CAS) with proximal versus distal cerebral protection in patients with high-risk, lipid-rich plaque.
Background Cerebral protection with filters partially reduces the cerebral embolization rate during CAS. Proximal protection
has been introduced to further decrease embolization risk.
Methods Fifty-three consecutive patients with carotid artery stenosis and lipid-rich plaque were randomized to undergo
CAS with proximal protection (MO.MA system, n  26) or distal protection with a filter (FilterWire EZ, n  27).
Microembolic signals (MES) were assessed by using transcranial Doppler during: 1) lesion wiring; 2) pre-dilation;
3) stent crossing; 4) stent deployment; 5) stent dilation; and 6) device retrieval/deflation. Diffusion-weighted
magnetic resonance imaging was conducted before CAS, after 48 h, and after 30 days.
Results Patients in the MO.MA group had higher percentage diameter stenosis (89  6% vs. 86  5%, p  0.027) and
rate of ulcerated plaque (35% vs. 7.4%; p  0.019). Compared with use of the FilterWire EZ, MO.MA significantly
reduced mean MES counts (p  0.0001) during lesion crossing (mean 18 [interquartile range (IQR): 11 to 30]
vs. 2 [IQR: 0 to 4]), stent crossing (23 [IQR: 11 to 34] vs. 0 [IQR: 0 to 1]), stent deployment (30 [IQR: 9 to 35] vs.
0 [IQR: 0 to 1]), stent dilation (16 [IQR: 8 to 30] vs. 0 [IQR: 0 to 1]), and total MES (93 [IQR: 59 to 136] vs. 16
[IQR: 7 to 36]). The number of patients with MES was higher with the FilterWire EZ versus MO.MA in phases 3 to
5 (100% vs. 27%; p  0.0001). By multivariate analysis, the type of brain protection was the only independent
predictor of total MES number. No significant difference was found in the number of patients with new post-CAS
embolic lesion in the MO.MA group (2 of 14, 14%) as compared with the FilterWire EZ group (9 of 21, 42.8%).
Conclusions In patients with high-risk, lipid-rich plaque undergoing CAS, MO.MA led to significantly lower microembolization
as assessed by using MES counts. (Carotid Stenting in Patients With High Risk Carotid Stenosis [“Soft Plaque”]
[MOMA]; NCT01274676) (J Am Coll Cardiol 2011;58:1656–63) © 2011 by the American College of Cardiology
Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.07.015Despite the lack of randomized controlled trials, cerebral
protection appears to have reduced neurological complica-
tions during carotid artery stenting (CAS) (1,2). However,
distal protection with filters did not fully prevent embolic
complications. Potential reasons include unprotected lesion
crossing, suboptimal apposition of the device to the arterial
wall, emboli smaller than filter porous size, and loss of
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accepted July 19, 2011.debris during filter recapture. These limitations have been
confirmed by previous studies with diffusion-weighted mag-
netic resonance imaging (DW-MRI), which revealed a 37%
mean rate of post-CAS new embolic lesions, mainly silent
and ipsilateral (3).
Proximal endovascular occlusion (PEO) is an alternative
approach that uses balloons to occlude both the external
carotid artery (ECA) and common carotid artery (CCA)
leading to blood flow arrest in the target internal carotid
artery (ICA). This technique may provide better protection
during all procedural steps and may be particularly indicated
for lesions at high risk of embolization, such as those with
high lipid content and irregular surfaces (4,5). Potential
drawbacks of PEO are patient intolerance to occlusion,
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sheath (8-F/9-F). Favorable results have been reported in
nonrandomized studies and single-center experiences with
30-day stroke and death rates as low as 1.4% (6–9).
Moreover, a lower rate of microembolic signals (MES) with
proximal occlusion compared with filter protection has been
demonstrated with transcranial Doppler (TCD) in unse-
lected patients undergoing CAS (10). Thus, the aim of this
study was to randomly compare PEO versus filter protection
during CAS in patients with lipid-rich stenosis deemed at
potential high risk of embolic complications.
Methods
Study patients. From February 2009 to March 2010, a
total of 120 consecutive patients were scheduled for CAS
because of carotid artery stenosis 50% (according to
Doppler ultrasound) in symptomatic patients and 75% in
asymptomatic patients. Fifty-three patients had a lipid-rich
plaque at computed tomography angiography (CTA) de-
fined as a plaque with 50 Hounsfield units (HU) (11,12)
and were enrolled into the study and randomly assigned to
receive distal protection using the FilterWire EZ (Boston
Scientific Corporation, Santa Clara, California) (n  27) or
proximal protection with the MO.MA system (Invatec,
Roncadelle, Brescia, Italy) (n 26). Exclusion criteria were:
myocardial infarction 72 h before CAS, major neurological
deficit (scores on the National Institutes of Health stroke
scale 15 or the modified Rankin Scale 3), stroke or
retinal embolism within 1 month before the index proce-
dure, contralateral ICA occlusion, severe disease of the
ipsilateral ECA, and intracranial stenosis of the ipsilateral
CCA requiring treatment.
The carotid Wallstent (Boston Scientific Corporation)
was used in all patients. The study endpoint was the MES
load, as a surrogate of cerebral embolization, assessed by
TCD during CAS.
Informed written consent was given by all patients, and
the protocol was approved by the local ethical committee.
CAS protocol. In the FilterWire EZ group, the device
was positioned in the distal ICA through a standard
guide/sheath. The MO.MA (9-F in 19 patients and 8-F
in 7 patients) was positioned in the CCA with the single
marker of the distal balloon located in the ECA, aiming
at fully excluding all side branches. After ECA occlusion
was confirmed by using contrast injection, the CCA
balloon was inflated. A second injection of contrast in the
CCA was performed to test proximal occlusion to look
for contrast stagnation. Clinical status and hemodynamic
parameters (ICA back pressure) were monitored for 30 s. If
occlusion intolerance did not occur, a 0.014-inch guide wire
was advanced through the lesion and positioned in the distal
ICA. Pre-dilation was left to the operator’s discretion and
performed with 4.0  40 mm coronary balloons. After
deployment, all stents were dilated with a 5.0 or 5.5 mm
Sterling balloon (Boston Scientific Corporation). Filter-Wire EZ was retrieved through a
4.3-F dedicated catheter; in the
MO.MA group, aspiration of
60 ml of blood was performed
through the guiding catheter
and, if no debris was found in the
last basket, the occlusion balloon
was deflated. An additional 20 ml
of blood aspiration was per-
formed if debris were found in
the last basket.
All patients were treated with
aspirin 100 mg/day plus clopi-
dogrel 75 mg/day or ticlopidine
250 mg for at least 10 days before
CAS and 1 month afterward.
Statins were given to all patients
(81% were receiving statins be-
fore study enrollment). During
CAS, patients received intrave-
nous heparin (5,000 U) to main-
tain the activated clotting time
250 s. Atropine (0.5 to 1 mg)
was injected intravenously im-
mediately before stent dilation.
In all patients, a neurological
examination was conducted by a
neurologist before and after CAS and at 30 days.
Computed tomography angiography. Scanning was per-
formed with a 64-slice multidetector computed tomography
(CT) scan (VCT XT, GE Medical System, Milwaukee,
Wisconsin). Image datasets were analyzed using volume-
rendering, multiplanar reconstruction and vessel analysis
software. Carotid stenosis severity and composition were
assessed using magnified cross-sectional CT images ob-
tained at the most severe narrowing site. Their density was
measured in HU using a fixed pixel lens averaging 3
measurements. A lesion with 50 HU was defined as a
lipid-rich plaque (11–13).
Transcranial Doppler. Two 2-MHz transducers con-
nected to TCD equipment (MultiDop T, DWL, Sipplin-
gen, Germany) fitted on a headband and placed on the
temporal bone window were used for bilateral continuous
measurement of flow velocity in the ipsilateral M1 segment
of the middle cerebral artery and contralateral A1 segment
of the anterior cerebral artery. Assessment of MES was
carried out from the ipsilateral middle cerebral artery,
whereas flow velocity assessment of the contralateral ante-
rior cerebral artery was used for detecting activation of the
collateral pathway via the anterior communicating artery
during proximal occlusion. Assessment of MES was per-
formed in the ipsilateral middle cerebral artery (14,15)
during the following CAS steps: 1) lesion crossing with the
FilterWire EZ or with a standard 0.014-inch wire in the
MO.MA group after CCA occlusion; 2) lesion pre-dilation;
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Contrast injection during CAS in the FilterWire EZ group
increased Doppler signal intensity, leading to a possible
uncorrected evaluation of MES. Therefore, these signals
were excluded from final analysis. Some Doppler signals
could not be counted individually in the specific procedural
steps. Thus, 1 s of microembolic shower was considered as
10 MES. Macroemboli (emboli that partially or completely
obstructed the middle cerebral artery [16]) were also
assessed.
Radiological assessment. Cerebral DW-MRI, including
1-weighted and T2-weighted fluid attenuated inversion
ecover and diffusion-weighted sequences, was assessed by
n experienced neuroradiologist aware of the study purpose
ut blinded to neurosonological and clinical data. All
agnetic resonance scans were performed the day before
AS, within 48 h after CAS, and at 30 days. New cerebral
esions were evaluated and categorized according to maximal
iameter (5, 5 to 10, and 10 mm), number, and location
inside or outside the vascular territory of the target artery).
tatistical analysis. A sample size of at least 24 patients
per group was calculated to assess as significant (p  0.05)
a difference in MES between groups equal to 1 SD
(corresponding to about 84 counts [10]) with a power
90% by using the Student t test. Numerical data are
summarized as mean  SD or median (interquartile range
[IQR]) as specified. Categorical data are summarized as
numbers and percentages. Clinical characteristics and MES
counts during CAS steps were compared between groups by
using the Student t test. Due to the skewed MES distribu-
tion, the results were confirmed by using the Wilcoxon rank
sum test. For comparing MES in each CAS step, the
Bonferroni correction for multiple testing was applied, thus
considering p values 0.008 as significant. Categorical data
were compared by using the chi-square test or Fisher exact
test, as appropriate. Predictors of MES were assessed by
multivariate covariance analysis considering age, high-risk
surgical status, lesion length, lesion eccentricity and severity,
lesion pre-dilation, and type of protection device. MES
values were log-transformed before analysis. All tests were
2-sided, and p values 0.05 were considered significant,
unless otherwise specified. All analyses were performed
using SAS version 9.13 (SAS Institute Inc., Cary, North
Carolina).
Results
Patients’ clinical characteristics are reported in Table 1. The
only difference in clinical variables was a significantly higher
rate of hypertension in the filter group. Lesion characteris-
tics and CAS procedural variables are reported in Table 2
and Figure 1. In the MO.MA group, CTA showed a higher
stenosis area (89% vs. 86%; p  0.027) by using the ECST
method and rate of ulcerated plaque (7.4% vs. 35%; p 
0.019). Technical success (30% post-CAS diameter ste-
nosis) was achieved in all patients.Clinical outcome. Two major complications occurred: 1
intraprocedural ipsilateral retinal embolism in the filter
group and 1 cardiac death due to acute myocardial infarction
25 days after CAS in the MO.MA group. A transient mild
gait disorder occurred in 1 patient in the filter group 48 h
after the procedure. The PEO was well tolerated in all but
1 patient who showed the lowest mean back pressure (32
mm Hg) and developed transient aphasia and right sensory
deficit during debris aspiration, which immediately resolved
after CCA balloon deflation. In the MO.MA group, the
mean back pressure was 50.8  11 mm Hg.
Microembolic signals. The percentage of patients with at
least 1 MES during all CAS phases ranged from 81% to
100% in the FilterWire EZ group and from 27% to 96% in
the MO.MA group (Table 3). Overall, there were a signif-
icantly lower number of patients with at least 1 MES in the
MO.MA group compared with the FilterWire EZ group in
phases 3, 4, and 5.
In the MO.MA group, the mean number of MES was
significantly lower (p  0.0001) in phase 3 (23 [IQR: 11
to 34] vs. 0 [IQR: 0 to 1]), 4 (30 [IQR: 9 to 35] vs. 0
[IQR: 0 to 1]), and 5 (16 [IQR: 8 to 30] vs. 0 [IQR: 0 to
1]), and significantly higher (p  0.0036) in phase 6 (2
[IQR: 1 to 6] vs. 8.5 [IQR: 3 to 17]), whereas no
difference was found in phase 2 as compared with the
FilterWire EZ group (7 [IQR: 6 to 12] vs. 0 [IQR: 0 to
1]) (Fig. 2).
By multivariate analysis, the type of embolic protection
was the only significant independent predictor of the mean
number of MES (Table 4). Patients in the MO.MA group
had an estimated 80% reduction in total MES number
compared with the FilterWire EZ group (–81.7 [95%
confidence interval: –88.6 to –70.7]; p  0.0001).
In the MO.MA group, carotid vessel anatomy did not
allow for inflation of the ECA balloon proximal to the
superior thyroid artery (STA) in 22 of 26 patients, 31% of
whom had residual flow from the ECA into the ICA as
Patient CharacteristicsTable 1 Patient Characteristics
Characteristic
FilterWire EZ
(n  27)
MO.MA
(n  26) p Value
Age (yrs) 69.4  4 68.2  7 0.673
Age 80 yrs 3 (11) 2 (7.7) 0.990
Male 20 (74) 22 (85) 0.344
Hypertension 23 (85) 15 (58) 0.026
Diabetes 7 (26) 6 (23) 0.890
Hypercholesterolemia 25 (92) 25 (96) 1.000
Smoking 7 (26) 11 (42) 0.208
Coronary artery disease 19 (70) 13 (50) 0.129
Previous CABG 9 (33) 4 (15) 0.230
Previous PTCA 8 (30) 8 (31) 0.928
Symptomatic patients 2 (7) 4 (15) 0.420
High surgical-risk patients 14 (51) 8 (31) 0.119
Values are mean  SD or n (%).
CABG  coronary artery bypass graft; PTCA  percutaneous transluminal coronary angioplasty.demonstrated by using contrast injection (Fig. 3). No
tid Sur
matic C
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count. The 2 patients with retinal embolism and gait
disorder had the highest MES count during stent crossing.
No macroemboli were observed during all procedures.
Lesion Characteristics and Procedural DataTable 2 Lesion Characteristics and Procedu
Characteristic FilterW
Stenosis assessment by Doppler ultrasound
PSV (m/s)
EDV (m/s)
Diameter stenosis (%)
Stenosis assessment by CTA
MLA (mm2) 3
MLD (mm) 2
Diameter stenosis (ECST, %)
Diameter stenosis (NASCET, %)
Hounsfield units 31.7
Long lesion (15 mm)
Lesion eccentricity (1.2)
Ulceration/thrombus
Type I aortic arch
Variants of Willis circulation
Stenosis pre-dilation
Procedural time (s)*
Occlusion time (s)
Macroscopic evidence of debris
Values are mean  SD, mean  SD (range), or n (%). *Procedural tim
bifurcation and its retrieval.
CTA  computed tomography angiography; ECST  European Caro
MLD  minimal lumen diameter; NASCET  North American Sympto
Figure 1 Carotid Vessel Evaluation by CTA and Doppler Ultraso
Computed tomography angiography (CTA) curved multiplanar reconstruction of caro
corresponding color Doppler ultrasound imaging (lower strip) in 4 study patients.Radiological assessment. Cerebral DW-MRI, performed
in 35 of 53 patients (66% [21 and 14 in the FilterWire EZ
and MO.MA group, respectively]) at 48 h and 30 days after
CAS, showed 45 new lesions in 11 of 35 patients (31.4%)
ata
Z (n  27) MO.MA (n  26) p Value
0.9 3.3 0.8 0.143
0.3 1.2 0.4 0.493
6 88 6 0.199
1.28 3.57 1.81 0.342
0.41 1.89 0.3 0.431
5 89 6 0.027
8.8 74 12 0.179
(19–50) 31.7 11.7 (14–50) 1.000
8) 14 (54) 0.678
7) 17 (65) 0.922
.4%) 9 (35%) 0.019
4) 22 (87) 0.344
6) 10 (38) 0.328
6) 10 (38) 0.328
236 — —
602 223 —
6) 7 (27) 0.934
ed as the time interval between guide/sheath positioning below the
gery Trial; EDV  end-diastolic velocity; MLA  minimal lumen area;
arotid Endarterectomy Trial; PSV  peak systolic velocity.
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follow-up in either group. Thirty-eight new lesions were
found in 9 of 21 patients (42.8%) in the filter group,
while 7 new lesions were detected in 2 of 14 (14.3%)
MO.MA group patients (Fisher exact test: p  0.14).
ost (78%) of the new lesions occurred in the target
essel territory and were silent in all but 1 case. Forty-one
f 45 (91.1%) lesions had a diameter 10 mm. The
ilterWire EZ patient with retinal embolism had a
egative DW-MRI study, whereas the patient with gait
isorder showed bilateral lesions involving the anterior
nd posterior circulation.
iscussion
his is the first randomized study comparing 2 different
rain protection devices in patients with high-risk, lipid-
Patients With Detectable MESDur ng the Different Phases of CASTable 3 Pati s With Detectable MESDuring the Different Phases of CAS
Steps
FilterWire EZ
(n  27)
MO.MA
(n  26) p Value
Lesion wiring 26 (96%) 19 (73%) 0.145
Pre-dilation* 6/7 (86%) 4/10 (40%) 0.578
Stent crossing of the lesion 27 (100%) 7 (27%) 0.0001
Stent deployment 27 (100%) 7 (27%) 0.0001
Stent post-dilation 26 (96%) 7 (27%) 0.0001
Device retrieval/deflation 22 (81%) 25 (96%) 0.721
Values are n (%). *Pre-dilation: n 7 patients in the FilterWire EZ group and n 10 in the MO.MA
group.
CAS  carotid artery stenting; MES  microembolic signals.
Figure 2 MES Counts During Carotid Stenting Phases
The median and interquartile range of each phase microembolic signals (MES) cou
and in the FilterWire EZ group (red box plots). Statistical significance is indicatedrich lesions undergoing CAS. Plaque composition was
assessed with CTA, and 50 HU was considered an estab-
lished cutoff point for high lipid content (11,12). Given the
low rate of clinically manifest embolic complications during
CAS (1,2), the number of MES detected by TCD was
used as a surrogate of cerebral embolization. The Wall-
stent was used in all patients to standardize treatment
strategy and reduce confusing factors. This stent was
chosen because of its closed design with the smallest cell
area that may achieve better lesion coverage and reduce
plaque prolapse.
Our study found that CAS with PEO was associated
with a significantly lower MES rate compared with the
FilterWire EZ, suggesting better brain protection. The
reported in the MO.MA group (green box plots)
ch phase. dep’t  deployment.
Predictors of Total MESTable 4 Predictors of Total MES
Variable
Estimated
Effect (%) 95% CI p Value
Age (1-yr increment) –0.4 –3.4 to 2.8 0.822
HSR versus LSR –12.2 –52 to 60.9 0.677
Lesion length (15 vs. 15)* –16.6 –49.6 to 37.9 0.482
Lesion eccentricity (1.2 vs. 1.2)* 52.7 –10.6 to 161 0.128
Stenosis diameter by ECST
(1% increment)*
–0.5 –4.6 to 3.8 0.826
Pre-dilation (yes vs. no) –18.4 –51.4 to 36.9 0.445
Protection device
(MO.MA vs. FilterWire EZ)
–81.7 –88.6 to –70.7 0.0001
Evaluated by using multivariate analysis of covariance. *Lesion length, lesion eccentricity, and
percentage diameter stenosis were assessed using computed tomography angiography.
HSR  high surgical risk; LSR  low surgical risk; other abbreviations as in Tables 2 and 3.nt are
for ea
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through 4, similar in both groups in phase 2, and signifi-
cantly lower in the filter group in phase 6.
Lesion crossing. If a filter is used, lesion crossing with a
standard coronary wire or the device itself is performed
without any protection. This method may be associated
with a substantial embolization risk, especially in tight and
soft/ulcerated plaques (17,18). The finding that MES num-
ber in the FilterWire EZ group was similar to that reported
in unprotected CAS or in CAS performed with different
distal protection devices (10,19–21) confirms that this
phase is a clear source of embolization. On the contrary,
PEO has the advantage of significantly reducing risk before
any device is advanced through the lesion. This may explain
the significantly lower number of MES in the MO.MA
group compared with the FilterWire EZ group.
Stent deployment and dilation. Previous TCD studies
showed that stent deployment and dilation are the steps
with higher embolization risk (10,19–21). Because we used
the same type of stent and implantation technique, MES
count difference in these phases should be largely attributed
to the type of brain protection. Use of MO.MA almost
abolished MES compared with FilterWire EZ, thus con-
firming the superiority of the former device. Similar results
have been reported by Ribo et al. (22), who used reversal
flow technique during transcervical CAS although they did
not report any quantitative data. We separately assessed the
role of stent crossing and deployment and found that both
steps cause a similar rate of microembolization. Interest-
ingly, the 2 FilterWire EZ patients with clinical events had
the highest MES counts during stent crossing. It is note-
worthy that MES number in the FilterWire EZ group was
Figure 3 Angiographic Sequence of Carotid Stenting Performed
(A) Baseline angiography (arrow indicates superior thyroid artery [STA]). (B) Inflati
Flow arrest is confirmed by blood pressure drop (frame) and contrast stagnation. N
(C and D) Progressive contrast dilution indicating collateral flow from STA to ICA (somewhat less than that reported with the first-generationdevice (FilterWire XL) (10,20). This finding may be due to
improvement in the filter design.
Lesion pre-dilation. Lesion pre-dilation is performed in
30% to 70% of CAS procedures (2) and is generally
preferred in cases of severe stenosis and calcified vessel to
facilitate stent crossing and deployment. This phase has also
been shown to be at risk of embolization (19–21). Only a
trend in favor of the MO.MA was found during this phase,
which may be due to the small number of patients receiving
balloon pre-dilation in both groups.
Device retrieval/deflation. Differently from the other
CAS phases, device retrieval/deflation was associated with a
significantly higher MES count in the MO.MA group and
a surprisingly small number of MES in the FilterWire EZ
group. A similar trend, although not statistically significant,
was reported by Schmidt et al. (10); Ribo et al. (22)
described short clusters of microemboli at balloon deflation.
Potential explanations include suboptimal debris aspiration
before balloon deflation, atherosclerotic disease of the com-
mon carotid artery at the site of balloon inflation, and
“washout” of plaque debris prolapsing through the stent at
the time of blood flow restoration.
Role of ECA exclusion. Occlusion of the ECA by balloon
inflation is a key step of PEO. Parodi et al. (23) reported
that when the CCA only was occluded, ICA flow from the
ECA was observed in most patients, potentially leading to
debris embolization. Because the STA is the first ECA
branch, the balloon should be inflated before its take-off to
achieve ECA exclusion. In this study, STA was not ex-
cluded in 84% of cases because it took off from the ECA
ostium or distal CCA (24). Indeed, angiography demon-
strated residual flow from STA to ICA in 30% of these
MO.MA (Patient #3)
xternal carotid artery (ECA) and common carotid artery (CCA) balloons.
at STA is still patent due to its origin close to ECA ostium.
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patients, suggesting a minor clinical role of STA patency.
Diffusion-weighted MRI. New cerebral ischemic lesions,
ainly silent, have been found by using DW-MRI after
ither diagnostic or interventional procedures of extracranial
arotid arteries (25). A systematic review by Schnaudegel et
l. (3), which included 1,363 patients undergoing CAS,
eported a 37% mean rate of new ischemic lesions. These
esions were found both in and outside the target vessel
erritory, suggesting suboptimal brain protection in the
ormer case and a role of complex anatomy, and diffuse
isease of the aortic arch and supra-aortic vessels as sources
f embolization in the latter case. We found new ischemic
esions in 31% of patients (42.8% in the FilterWire EZ
roup and 14.3% in the MO.MA group). This difference
as not statistically significant. The lesions were ipsilateral
n 78% of patients, underlining the CAS-associated risk and
he need of further cerebral protection improvement. Sim-
lar data were reported by Faraglia et al. (26) and Leal et al.
27), who found new lesions in 13.9% and 12.5% of patients
ndergoing trans-cervical CAS under flow reversal protec-
ion, respectively.
redictors of total number of MES. Several clinical and
angiographic variables (age, high-risk surgical status,
stenosis severity, length and eccentricity, lesion pre-
dilation, and type of protection device) have been found
to predict neurological CAS complications and may have
influenced our results. Interestingly, by multivariate anal-
ysis, the only predictor of MES count was the type of
brain protection. Indeed, CAS with MO.MA was asso-
ciated with an 80% reduction in TCD-detected cerebral
embolization.
Clinical implications. Although there is evidence that
MES represent microemboli, the clinical impact of cerebral
microembolization during CAS is not established. How-
ever, cerebral microemboli have been involved in cognitive
decline after heart surgery, carotid endarterectomy, and
CAS (28,29). Multiple risk factors, including age, hyper-
tension, and/or diabetes affecting cerebral microcirculation,
may increase brain vulnerability to ischemic injury from
microemboli in patients undergoing CAS. If this holds true,
MES reduction during CAS should be pursued to improve
clinical outcome.
Study limitations. All CAS were performed by experi-
enced operators and only one type of filter was used. Thus,
our results should be interpreted with caution and may be
different with other distal protection devices.
Conclusions
Microembolization was significantly reduced by MO.MA
compared with FilterWire EZ during CAS of high-risk,
lipid-rich lesions, suggesting that PEO may provide better
brain protection.Reprint requests and correspondence: Dr. Piero Montorsi,
Department of Cardiovascular Sciences, University of Milan,
Centro Cardiologico Monzino, IRCCS, Via Parea, 4 20138
Milan, Italy. E-mail: piero.montorsi@unimi.it.
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